The Next Generation in

 Cancer Therapy

Cells - Apoptosis 2.png
 

ABOUT ONCOSENX

OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.

 

OUR MISSION

The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease.  The next generation of cancer therapies has begun...

 

SCIENCE

shutterstock_433526728.jpg

OUR SYSTEM

 

Our system is comprised of two main components: An untargeted non-toxic lipid nanoparticle and a highly targeted DNA payload.

 

CELL TARGETING

DNA plasmids encode an inducible death protein under a promoter that is active in the target cell population. We are initially targeting cells that are transcriptionally active for p53.

Cells are killed via apoptosis with caspase 9.

We can use our DNA payload to effectively implement logic gates (IF/OR/AND). This allows us to precisely target cell populations based on their genetic activity without harming adjacent cells.

OncoSenX_PIC_01_.jpg
 
 

DELIVERY

Our patented lipid nanoparticle (LNP) is the transfection agent that efficiently delivers our non-integrating DNA plasmid to cancer cells

These LNPs have been shown to be non-immunogenic, even with adjuvant, and are non-toxic at doses up to 10x expected human therapeutic dose in rodents and non-human primates.

OncoSenX_PIC_02_.jpg
 
 

SAFETY

Anti-LNP antibody & neutralization assays:

  • Virtually no antibody response to LNPs in immune-competent mice, even with adjuvants
  • Neutralization requires very high antibody concentration
  • “Vaccination” against LNPs does not reduce efficacy
  • Repeat dosing is effective and well tolerated

CARPA Assays

LNPs is generally less reactive than other lipid drug formulations

Non-Human Primate Studies were Initiated late August, 2017 by RxGen and concluded mid-September. Analysis is still underway but no visible toxicity is seen in animals receiving full treatment course at ten times the normal human dose.

OncoSenX_PIC_03_.jpg

Our Partners

 

 
 
 
 

OISIN BIOTECHNOLOGIES

Oisín Biotechnologies' ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself.  

 

Entos Pharmaceuticals.jpg

ENTOS PHARMACEUTICALS

Entos Pharmaceuticals is a healthcare biotechnology company that develops precision breakthrough therapies through strategic development partnerships.

 
 

METHUSELAH FUND

The Methuselah Fund is designed to accelerate results in the longevity field, extending the healthy human lifespan. Their success is measured by financial return on investments and furthering the mission, with the mission being the priority. Their network of mission-oriented individuals contains many angels, super-angels and professional investors.

 

M Foundation Logo with Background.jpg

Methuselah Foundation

The Methuselah Foundation is a forward thinking medical public non-profit Foundation that looks for, examines, carefully tests, and implements high-leverage interventions that spur concrete progress in the short term and causes synergistic ripple effects over time in the longevity and health-span field.

 
 
sens.jpg

SENS FOUNDATION

The SENS Research Foundation conducts research that emphasizes the application of regenerative medicine to age-related disease, with the intent of repairing underlying damage to the body's tissues, cells, and molecules. Its goal is to help build the industry that will cure the diseases of aging. 

 

University of Alberta.jpg

UNIVERSITY OF ALBERTA, CANADA

The Lewis lab at the University of Alberta utilizes real-time intravital imaging of the tumour microenvironment to learn about the critical steps of cancer progression, including the growth of new blood vessels and the gain of tumor cell motility that leads to metastasis. It is investigating novel nanoparticles that are being developed for the early detection of prostate cancer, drug delivery, and the in vivo study of tumor cell invasion and metastasis. 

 

TEAM

shutterstock_580814518.jpg
  MATTHEW SCHOLZ - Chief Executive Officer   Matt is a co-founder of OncoSenX and serves as CEO and Chairman. A serial entrepreneur with a background in computer security and immunology, Matt is also the founder and CEO of Oisín Biotechnoligies and former CEO of Immusoft, a biotech firm developing a breakthrough technology that will turn a patient's B cells into miniature drug factories. He’s a graduate of the University of Washington and a frequent speaker at the UW School of Business, while also serving as a mentor for the Thiel Fellowship program.

MATTHEW SCHOLZ - Chief Executive Officer

Matt is a co-founder of OncoSenX and serves as CEO and Chairman. A serial entrepreneur with a background in computer security and immunology, Matt is also the founder and CEO of Oisín Biotechnoligies and former CEO of Immusoft, a biotech firm developing a breakthrough technology that will turn a patient's B cells into miniature drug factories. He’s a graduate of the University of Washington and a frequent speaker at the UW School of Business, while also serving as a mentor for the Thiel Fellowship program.

  JOHN D. LEWIS, PhD - Chief Science Officer   Dr. John Lewis the co-founder of OncoSenX and heads its cancer-fighting platform technology development and clinical research. Dr. Lewis also holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta. He is an Associate Professor in the Department of Oncology and chairs the Alberta Prostate Cancer Research Initiative. Dr. Lewis has also founded three Canadian biotechnology companies.   

JOHN D. LEWIS, PhD - Chief Science Officer

Dr. John Lewis the co-founder of OncoSenX and heads its cancer-fighting platform technology development and clinical research. Dr. Lewis also holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta. He is an Associate Professor in the Department of Oncology and chairs the Alberta Prostate Cancer Research Initiative. Dr. Lewis has also founded three Canadian biotechnology companies.

 

  GARY C. HUDSON - Executive Chairman   Gary Hudson is co-founder and Board Member of Oisin Biotechnologies. Mr. Hudson is also active in several non-profits focusing on age-related disease. Mr. Hudson has won several awards during his career including Laurel Award from Aviation Week and Space Technology, the Founder’s Award from the Space Frontier Foundation and was inducted into the International Space Hall of Fame in 2014 for his contributions to the field. 

GARY C. HUDSON - Executive Chairman

Gary Hudson is co-founder and Board Member of Oisin Biotechnologies. Mr. Hudson is also active in several non-profits focusing on age-related disease. Mr. Hudson has won several awards during his career including Laurel Award from Aviation Week and Space Technology, the Founder’s Award from the Space Frontier Foundation and was inducted into the International Space Hall of Fame in 2014 for his contributions to the field. 

 
  STEPHEN HILBERT - President of Corporate Development   Mr. Hilbert heads up corporate development for Oisin Biotechnologies. He has served as a business advisor to Oisin since its inception and has served on several biotechnology company advisory boards specializing in business strategy and capital formation. Prior to Oisin in the Biotech space, Mr. Hilbert has served as corporate advisor to Immusoft and Kineta where he most recently served as VP of Corporate Development. His career spans over 10 years in biotech advisory and 18 years in the banking business where he served as trusted advisor creating investment strategies and structures for accredited investors around the globe.

STEPHEN HILBERT - President of Corporate Development

Mr. Hilbert heads up corporate development for Oisin Biotechnologies. He has served as a business advisor to Oisin since its inception and has served on several biotechnology company advisory boards specializing in business strategy and capital formation. Prior to Oisin in the Biotech space, Mr. Hilbert has served as corporate advisor to Immusoft and Kineta where he most recently served as VP of Corporate Development. His career spans over 10 years in biotech advisory and 18 years in the banking business where he served as trusted advisor creating investment strategies and structures for accredited investors around the globe.

  ERIC GARCIA - Chief Operating Officer   Eric Garcia is the Chief Operating Officer and Treasurer of OncoSenX.  He has responsibility for the company’s finances and business operations.  Mr. Garcia also helped start Oisin Biotechnologies, serving as its COO.  Prior to Oisin Biotechnologies Mr. Garcia was the Chief Financial Officer for the immunotherapy biotech, Immusoft Corporation.  Outside biotechnology, Mr. Garcia has worked in banking, financial management and public policy.

ERIC GARCIA - Chief Operating Officer

Eric Garcia is the Chief Operating Officer and Treasurer of OncoSenX.  He has responsibility for the company’s finances and business operations.  Mr. Garcia also helped start Oisin Biotechnologies, serving as its COO.  Prior to Oisin Biotechnologies Mr. Garcia was the Chief Financial Officer for the immunotherapy biotech, Immusoft Corporation.  Outside biotechnology, Mr. Garcia has worked in banking, financial management and public policy.

OVCOSENX_IMG_2018_02.jpg

CORPORATE HEADQUARTERS

800 5th Avenue, Suite 4100

Seattle, WA 98104

 
 

 

INQUIRIES

 

Name *
Name
GDPR Paragraph *
OncoSenX will use the information you provide to an answer your inquiry. For further questions email us at: info@oncosenx.com. Privacy Policy.